SSII

SS Innovations International, Inc. (SSII) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. SS Innovations International, Inc. (SSII) designs, manufactures, and markets the "SSi Mantra" surgical robotic system and related instruments. The company operates as a single reportable segment, with 99% of revenue derived from India. SSII is listed on the Nasdaq Capital Market under the ticker "SSII" and is classified as a smaller reporting company.

Key Financial Metrics

Debt and Liquidity: The company maintains a bank overdraft facility of approximately $11.16 million. Liquidity was significantly bolstered by a private placement in March 2026, generating net proceeds of $18.45 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 117% year-over-year, driven by the sale of 18 SSi Mantra systems and increased instrument sales.
• Profitability Improvement: Net loss narrowed by 37% to $3.58 million, primarily due to a $4.24 million increase in gross profit.
• Expense Increases: Stock compensation expense rose to $3.14 million (from $2.38 million) due to new Restricted Stock Awards. SG&A expenses increased to $4.50 million due to legal, underwriting, and business event costs.
• Tax Expense: The company recorded an income tax expense of $151,352, compared to nil in the prior year, as Indian operations generated taxable profits.
• Balance Sheet: Total assets grew to $90.5 million from $74.2 million, largely due to the cash infusion from the private placement.

Guidance, Outlook, and Risks

• Capital Raise: On March 6, 2026, the company completed a private placement of 5.77 million shares, raising $18.45 million net. Proceeds are designated for working capital and expansion into U.S. and EU markets.
• Going Concern: Despite the recent capital raise, management states that existing resources may not be sufficient to fund operations for the next 12 months without further funding. The financial statements are prepared on a going concern basis, but substantial doubt remains regarding the ability to continue as a going concern without additional capital.
• Regulatory Outlook: The company is pursuing FDA approval in the U.S. and CE mark approval in the EU, which are critical for future growth.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including inadequate design of controls for U.S. GAAP application and lack of written documentation. Remediation efforts, including ERP implementation, are underway.
• Legal Contingencies: A transfer pricing dispute with Indian tax authorities remains pending before the Income Tax Appellate Tribunal (ITAT) regarding an adjustment of approximately $505,000. Management believes its position will be sustained.

Investor Verification Checklist

• Cash Burn Rate: Verify the runway provided by the $18.45 million raise against the current operating cash burn of ~$2.3 million per quarter.
• Revenue Recognition: Review the breakdown of deferred revenue ($11.1 million) and the timing of recognition for system sales versus warranty/lease income.
• Internal Control Remediation: Monitor progress on the remediation of material weaknesses in internal controls, specifically regarding revenue recognition and segregation of duties.
• Regulatory Milestones: Track the status of FDA and CE mark approvals, which are prerequisites for significant international expansion.
• Related Party Transactions: Review the significant related party transactions, including the private placement to directors and affiliates, and the conversion of notes to equity.